A critical evaluation of nemolizumab for prurigo nodularis

References

• Kwatra SG. Breaking the itch-scratch cycle in Prurigo Nodularis. N Engl J Med. 2020 Feb 20;382(8):757–758. doi: 10.1056/NEJMe1916733
   PubMed Web of Science ®Google Scholar
• Pereira MP, Steinke S, Zeidler C, et al. European Academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1059–1065.
   PubMed Web of Science ®Google Scholar
• Joel MZ, Hydol-Smith J, Kambala A, et al. Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the All of Us research program. J Am Acad Dermatol. 2023 Jul 06;89(5):1056–1058. doi: 10.1016/j.jaad.2023.06.045
   PubMed Web of Science ®Google Scholar
• Ständer S, Augustin M, Berger T, et al. Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. JAAD Int. 2021 Mar 01;2:28–30.
   PubMedGoogle Scholar
• Huang AH, Canner JK, Khanna R, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol. 2020 Feb;140(2):480–483.e4.
   PubMed Web of Science ®Google Scholar
• Froelunde AS, Vestergaard C. Prurigo nodularis: the epidemiology of an under-recognized disease. Br J Dermatol. 2022 Nov;187(5):e171–e172. doi: 10.1111/bjd.21843
   PubMed Web of Science ®Google Scholar
• Huang AH, Williams KA, Kwatra SG. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020 Dec;83(6):1559–1565. doi: 10.1016/j.jaad.2020.04.183
   PubMed Web of Science ®Google Scholar
• Boozalis E, Tang O, Patel S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J Am Acad Dermatol. 2018 Oct;79(4):714–719.e3.
   PubMed Web of Science ®Google Scholar
• Schuhknecht B, Marziniak M, Wissel A, et al. Reduced intraepidermal nerve fibre density in lesional and nonlesional prurigo nodularis skin as a potential sign of subclinical cutaneous neuropathy. Br J Dermatol. 2011 Jul;165(1):85–91.
   PubMed Web of Science ®Google Scholar
• Harris B, Harris K, Penneys NS. Demonstration by S-100 protein staining of increased numbers of nerves in the papillary dermis of patients with prurigo nodularis. J Am Acad Dermatol. 1992 Jan;26(1):56–8. doi: 10.1016/0190-9622(92)70006-2
   PubMed Web of Science ®Google Scholar
• Yosipovitch G. Prurigo nodularis: new treatments on the horizon. J Am Acad Dermatol. 2020 Apr;82(4):1035–1036. doi: 10.1016/j.jaad.2019.02.061
   PubMed Web of Science ®Google Scholar
• Agrawal D, Sardana K, Mathachan SR, et al. A case–control study addressing the population of epidermal and dermal inflammatory infiltrate including neural milieu in primary prurigo nodularis using S-100 and toluidine blue stain and its therapeutic implications. Int J Dermatol. 2023;62(11):1352–1358. doi: 10.1111/ijd.16834
   PubMed Web of Science ®Google Scholar
• Williams KA, Huang AH, Belzberg M, et al. Prurigo nodularis: Pathogenesis and management. J Am Acad Dermatol. 2020 Dec;83(6):1567–1575.
   PubMed Web of Science ®Google Scholar
• Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67. doi: 10.1080/17512433.2021.1852080
   PubMed Web of Science ®Google Scholar
• Molloy OE, Kearney N, Byrne N, et al. Successful treatment of recalcitrant nodular prurigo with tofacitinib. Clin Exp Dermatol. 2020 Oct;45(7):918–920.
   PubMed Web of Science ®Google Scholar
• Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part II. A comprehensive review. J Am Acad Dermatol. 2022 Feb;86(2):414–422. doi: 10.1016/j.jaad.2021.06.873
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Sakai K, Sanders KM, et al. Antipruritic effects of Janus kinase inhibitor Tofacitinib in a mouse model of psoriasis. Acta Derm Venereol. 2019 Mar 1;99(3):298–303. doi: 10.2340/00015555-3086
   PubMed Web of Science ®Google Scholar
• Rich RR, Fleisher TA, Shearer WT, et al. Clinical immunology e-book: principles and practice. 6th ed. Vol. 145. Elsevier Health Sciences; 2012. p. 82–88.
   Google Scholar
• Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011 Nov;165(5):990–6. doi: 10.1111/j.1365-2133.2011.10498.x
   PubMed Web of Science ®Google Scholar
• Agrawal D, Sardana K, Mathachan SR, et al. A prospective study examining the expression of STAT 1, 3, 6 in prurigo nodularis lesions with its immunopathogenic and therapeutic implications. J Cosmet Dermatol. 2022;21(9):4009–4015. doi: 10.1111/jocd.14709
   PubMed Web of Science ®Google Scholar
• Seif F, Khoshmirsafa M, Aazami H, et al. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017 Jun 21;15(1):23. doi: 10.1186/s12964-017-0177-y
   PubMedGoogle Scholar
• Qureshi AA, Abate LE, Yosipovitch G, et al. A systematic review of evidence-based treatments for prurigo nodularis. J Am Acad Dermatol. 2019 Mar;80(3):756–764.
   PubMed Web of Science ®Google Scholar
• Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J Am Acad Dermatol. 2021 Mar 01;84(3):747–760. doi: 10.1016/j.jaad.2020.07.025
   PubMed Web of Science ®Google Scholar
• Zeidler C, Yosipovitch G, Ständer S. Prurigo Nodularis and Its Management. Dermatol Clin. 2018 Jul;36(3):189–197. doi: 10.1016/j.det.2018.02.003
   PubMed Web of Science ®Google Scholar
• Ständer HF, Elmariah S, Zeidler C, et al. Diagnostic and treatment algorithm for chronic nodular prurigo. J Am Acad Dermatol. 2020 Feb 01;82(2):460–468. doi: 10.1016/j.jaad.2019.07.022
   PubMed Web of Science ®Google Scholar
• Labib A, Ju T, Vander Does A, et al. Immunotargets and therapy for Prurigo Nodularis. Immunotargets Ther. 2022;11:11–21. doi: 10.2147/ITT.S316602
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. Nat Med. 2023 May 01;29(5):1180–1190. doi: 10.1038/s41591-023-02320-9
   PubMed Web of Science ®Google Scholar
• Biazus Soares G, Yosipovitch G. A critical review of dupilumab for adult patients with prurigo nodularis. Expert Rev Clin Immunol. 2023 Oct;9:1–6. doi: 10.1080/1744666X.2023.2268291
   Google Scholar
• Husein-ElAhmed H, Steinhoff M. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatological Treat. 2022 Apr 03;33(3):1547–1553.
   PubMed Web of Science ®Google Scholar
• Cao P, Xu W, Jiang S, et al. Dupilumab for the treatment of prurigo nodularis: A systematic review. Front Immunol. 2023;14:1092685. doi: 10.3389/fimmu.2023.1092685
   PubMed Web of Science ®Google Scholar
• Chisolm MD SS. A review of the Current management and burden of Prurigo Nodularis in the United States. Supplements and Featured Publications. 2023.
   Google Scholar
• Kwatra S, Bordeaux Z, Pritchard T, et al. Efficacy, safety, and mechanism of action of abrocitinib in the treatment of prurigo nodularis and chronic pruritus of unknown origin. Presented at: European Academy of Dermatology and Venereology Congress 2023; Oct 11-14, 2023; Berlin, Germany.
   Google Scholar
• Vander Does A, Yosipovitch G. Failure of dupilimab with severe prurigo nodularis that responded well to Abrocitinib. Dermatitis®. 2023;34(6):567–567. doi: 10.1089/derm.2022.0065
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis, NCT05061693. ClinicalTrials.Gov, 2023. [cited 22 Dec 2023]. Available from: https://clinicaltrials.gov/study/NCT05061693
   Google Scholar
• Sardana K, Mathachan SR, Agrawal D. Treatment of recalcitrant paediatric prurigo nodularis with tofacitinib, an exquisite example of bench-to-bedside translation of JAK-STAT expression. Indian J Dermatol Venereol Leprol. doi: 10.25259/IJDVL_362_2023
   Google Scholar
• Agrawal D, Sardana K, Mathachan SR, et al. A case of recalcitrant prurigo nodularis with heightened expression of STAT 3 and STAT 6 and its dramatic response to Tofacitinib. Indian Dermatol Online J. 2023;14(4):564. doi: 10.4103/idoj.idoj_508_22
   PubMedGoogle Scholar
• Shea J, Frucht D, Duchett C. Cytokines and cytokine receptors in clinical immunology, principles and practice. 2nd ed. Basel, Switzerland: Karger AG; 2001. p. 1–22. Mosby Ch12 (1)
   Google Scholar
• Harrington R, Harkins P, Conway R. Janus kinase inhibitors in rheumatoid arthritis: an update on the efficacy and safety of Tofacitinib, Baricitinib and Upadacitinib. J Clin Med. 2023 Oct 23;12(20):6690. doi: 10.3390/jcm12206690
   PubMed Web of Science ®Google Scholar
• Frølunde AS, Wiis MAK, Ben Abdallah H, et al. Non-Atopic Chronic Nodular Prurigo (Prurigo Nodularis Hyde): A systematic review of best-evidenced treatment options. Dermatology. 2022;238(5):950–960. doi: 10.1159/000523700
   PubMed Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021 Oct 01;85(4):863–872. doi: 10.1016/j.jaad.2021.04.085
   PubMed Web of Science ®Google Scholar
• Celldex announces first patient dosed in phase 1 study of CDX-0159 in prurigo nodularis [Internet]. Celldex Therapeutic, Inc.; Dec 8, 2021
   Google Scholar
• Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Mar;57:101826.
   PubMedGoogle Scholar
• Hashimoto T, Nattkemper LA, Kim HS, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. Exp Dermatol. 2021 Jun;30(6):804–810.
   PubMed Web of Science ®Google Scholar
• Study to assess the efficacy, safety, and tolerability of Vixarelimab in reducing Pruritus in Prurigo Nodularis. ClinicalTrials.Gov #NCT03816891. Last Updated August 16, 2023.
   Google Scholar
• Yew YW, Yeo PM. Comparison between dupilumab and oral janus kinase inhibitors in the treatment of prurigo nodularis with or without atopic dermatitis in a tertiary care center in Singapore. JAAD Int. 2023 Dec;13: 13–14. doi: 10.1016/j.jdin.2023.06.005
   PubMedGoogle Scholar
• Keam SJ. Nemolizumab: first approval. Drugs. 2022 Jul 01;82(10):1143–1150.
   PubMed Web of Science ®Google Scholar
• Ständer S, Yosipovitch G, Legat FJ, et al. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis. N Engl J Med. 2020;382(8):706–716. doi: 10.1056/NEJMoa1908316
   PubMed Web of Science ®Google Scholar
• Serra-Baldrich E, Santamaría-Babí LF, Francisco Silvestre J. Nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and Prurigo Nodularis. Actas Dermosifiliogr. 2022 Jul;113(7):674–684. doi: 10.1016/j.ad.2021.12.014
   PubMed Web of Science ®Google Scholar
• Bağci IS, Ruzicka T. IL-31: a new key player in dermatology and beyond. J Allergy Clin Immunol. 2018 Mar 01;141(3):858–866.
   PubMed Web of Science ®Google Scholar
• Cheung PF, Wong CK, Ho AW, et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010 Jun;22(6):453–67.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Okayama Y, Kaminuma O, et al. Proteomic approach to FcεRI aggregation-initiated signal transduction cascade in human mast cells. Int Arch Allergy Immunol. 2009;Suppl 149(Suppl. 1):73–76. doi: 10.1159/000211376
   Google Scholar
• Raap U, Gehring M, Kleiner S, et al. Human basophils are a source of - and are differentially activated by - IL-31. Clin Exp Allergy. 2017 Apr;47(4):499–508.
   PubMed Web of Science ®Google Scholar
• Santamaria-Bab E-B, Silvestre JF. [Translated article] nemolizumab: an innovative biologic treatment to control interleukin 31, a key mediator in atopic dermatitis and Prurigo Nodularis. Actas Dermo-Sifiliográficas. 2022;113(7):T674. doi: 10.1016/j.ad.2022.06.001
   PubMed Web of Science ®Google Scholar
• Tsoi LC, Hacini-Rachinel F, Fogel P, et al. Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab. J Allergy Clin Immunol. 2022 Apr;149(4):1329–1339.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Alpizar S, Laquer V, et al. Pharmacokinetics, safety, efficacy, and biomarker profiles during nemolizumab treatment of atopic dermatitis in adolescents. Dermatol Ther. 2022 Mar 01;12(3):631–642. doi: 10.1007/s13555-021-00678-7
   PubMed Web of Science ®Google Scholar
• Saito T, Iida S, Terao K, et al. Dosage optimization of nemolizumab using population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling and simulation. J Clin Pharmacol. 2017 Dec;57(12):1564–1572.
   PubMed Web of Science ®Google Scholar
• Mullins TB, Sharma P, Riley CA, et al. Prurigo Nodularis. [Updated 2022 Sep 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459204/
   Google Scholar
• Morgan CL, Thomas M, Ständer S, et al. Epidemiology of prurigo nodularis in England: a retrospective database analysis. Br J Dermatol. 2022 Aug;187(2):188–195.
   PubMed Web of Science ®Google Scholar
• Ständer S, Ketz M, Kossack N, et al. Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis. Acta Derm Venereol. 2020 Nov 4;100(18):adv00309. doi: 10.2340/00015555-3655
   PubMedGoogle Scholar
• A study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN). Clinicaltrials.Gov #NTC03181503. Last updated February 19, 2020. Accessed September 15, 2023.
   Google Scholar
• An efficacy and safety study of Nemolizumab (CD14152) in participants with Prurigo Nodularis. ClinicalTrials.Gove #NCT04501666. Updated June 28, 2023.
   Google Scholar
• Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of Nemolizumab in patients with Prurigo Nodularis. N Engl J Med. 2023;389(17):1579–1589. doi: 10.1056/NEJMoa2301333
   PubMed Web of Science ®Google Scholar
• Galderma. Galderma announces positive data from phase III trial, demonstrating efficacy and safety of nemolizumab in patients with prurigo nodularis [internet]. Zug (Switzerland): Galderma; 2022.
   Google Scholar
• Galderma @ WCD 2023: late-breaking phase III results for nemolizumab monotherapy in prurigo nodularis show a significant proportion of itch-free patients by week 4 [Internet]. Galderma; Jul 4, 2023
   Google Scholar
• Ständer S, Yosipovitch G, Lacour JP, et al. Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances. J Eur Acad Dermatol Venereol. 2022 Oct 01;36(10):1820–1825. doi: 10.1111/jdv.18377
   PubMed Web of Science ®Google Scholar
• Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018 Oct;142(4):1121–1130.e7.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Matsumura T, Komazaki H, et al. Trial of Nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020 Jul 9;383(2):141–150. doi: 10.1056/NEJMoa1917006
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020 Jan 01;145(1):173–182. doi: 10.1016/j.jaci.2019.08.013
   PubMed Web of Science ®Google Scholar
• A study to evaluate the durability of response and safety of Nemolizumab for 24 weeks in participants with Prurigo Nodularis. ClinicalTrials.gov #NCT05052983. Updated June 23, 2023.
   Google Scholar
• Stander S. Nemolizumab monotherapy improves itch and skin lesions in patients with moderate-to-severe prurigo nodularis: results from a global phase 3 trial (OLYMPIA 1). Late-breaking abstract presented at EADV 2023; Berlin, Germany.
   Google Scholar
• A long-term study of nemolizumab (CD14152) in participants with prurigo nodularis (PN). Clinicaltrials.Gov #NTC04204616. [ updated Apr 24, 2023; cited 2023 Sep 15].
   Google Scholar
• Galderma announces topline results of OLYMPIA 2 study evaluating Nemolizumab in Prurigo Nodularis ( Press Release on Jun 22, 2022) https://www.chugai-pharm.co.jp/english/news/detail/20220622160000_930.html
   Google Scholar